Obagi Medical and DermFx Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ(TM)
MWN-AI** Summary
Obagi Medical, a leader in physician-dispensed skincare and part of Waldencast plc, has announced a strategic partnership with DermFx to implement the ALOHA Program focused on real-world evidence. This collaboration targets the evaluation of Obagi® saypha® MagIQ™, an innovative injectable hyaluronic acid product developed by Croma-Pharma GmbH. The ALOHA Program aims to translate clinical data from FDA trials into practical applications within dynamic med spa environments.
Erin Alonso, the founder and CEO of DermFx, expressed satisfaction with the partnership, highlighting that DermFx's expertise in aesthetic treatments complements Obagi's evidence-based approach. The partnership aims to deliver personalized patient care while leveraging cutting-edge protocols to elevate treatment outcomes. The program provides DermFx with valuable hands-on experience, standardized evaluation methods, and insights designed to boost patient satisfaction.
The ALOHA initiative is particularly beneficial for regional practices like DermFx, offering them access to advanced protocols and a supportive framework to compete effectively within the market dominated by larger groups. The collaboration showcases Obagi's commitment to improving aesthetic outcomes across various practice types, embodying their Aesthetics for All™ philosophy.
The innovative MACRO Core Technology utilized in the saypha® MagIQ™ injectables aims to yield natural results and consistent performance. Initial findings from the ALOHA Program will be shared at DermFx's internal meetings and regional events, demonstrating the enhanced value of these products and protocols to both practitioners and patients.
This partnership signifies a pivotal step in integrating cutting-edge aesthetic innovations into everyday practice, ultimately aiming to solidify Obagi Medical's position as a leader in the skincare market while empowering regional providers.
MWN-AI** Analysis
The recent collaboration between Obagi Medical and DermFx marks a significant advancement in the aesthetics and skincare market, particularly with the launch of the ALOHA Program focusing on the Obagi® saypha® MagIQ™ product. This partnership represents an innovative approach to bridging clinical research with real-world applications, positioning both companies to capitalize on emerging consumer trends in injectable aesthetic treatments.
Investors should view this collaboration as a strategic move that enhances Obagi Medical's market positioning within the competitive skincare landscape. By aligning with a well-regarded regional player like DermFx, which emphasizes patient-centered care and clinical expertise, Obagi can effectively demonstrate the value of its products in everyday settings. This initiative not only enhances brand credibility but also serves to drive patient satisfaction through evidence-based practices.
Moreover, the structured evaluation process outlined in the ALOHA program allows DermFx to capture real-world data, creating a feedback loop that could lead to further refinements in treatment protocols. Such data is invaluable in establishing market trust and can be leveraged for future marketing campaigns, bolstering Obagi's reputation as a leader in physician-dispensed skincare solutions.
For investors, the implications of this partnership are clear: increased demand for innovative, effective aesthetic treatments is anticipated, especially among independent medical practices striving to stay competitive against larger chains. Given Obagi's rapid growth trajectory—being recognized as the fastest-growing professional skincare brand—this collaboration may further accelerate its market share.
As the sector evolves, keeping an eye on the outcomes of the ALOHA program could yield insights into consumer preferences and treatment efficacy, allowing investors to anticipate trends and make informed decisions. Overall, this partnership positions Obagi Medical and DermFx favorably in a dynamic market, enhancing their ability to deliver high-impact skincare solutions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK and SUNSET BEACH, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced DermFx as a key partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. DermFx will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple locations and structured evaluation programs that will highlight the value of ALOHA to DermFx.
“This partnership with Obagi makes perfect sense for us. They're taking a thoughtful, evidence-based approach to introducing this innovative injectable, and as a strong regional leader with deep roots in Southern California, we have the clinical expertise and patient-focused environment to evaluate how trial data performs in real-world med spa settings,” said Erin Alonso, Founder, CEO & Family Nurse Practitioner at DermFx. “Our providers deliver advanced aesthetic treatments daily to thousands of loyal patients across our locations, emphasizing personalized care and outstanding results. That specialized, community-centered experience matters. The ALOHA Program is especially valuable for strong regional practices like ours, not just larger national groups, by providing access to cutting-edge protocols, real-world insights, and integrated skincare-injectable strategies that elevate patient outcomes and help independent med spas compete at the highest level. Obagi’s focus on inclusive, practice-driven evidence aligns perfectly with our dedication to exceptional, transformative patient care.”
The ALOHA Real-World Program is designed to give DermFx providers hands-on experience with Obagi® saypha® MagIQ™ while evaluating complete Obagi protocols. This approach aims to drive patient satisfaction and strengthen relationships between patients and their DermFx providers. The program includes a structured evaluation process across DermFx’s multiple locations, with standardized data capture and a demonstration of enhanced value for DermFx practice locations. DermFx will present initial findings at upcoming internal team meetings and regional events, highlighting the benefits of the new protocols and product within the DermFx network.
“Partnering with DermFx is a clear statement of our Aesthetics for All™ ethos and a focus on all practice types delivering exceptional aesthetic outcomes,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA program will serve as a platform for a differentiated launch strategy and underscore Obagi Medical’s commitment to delivering innovative products across every facet of skincare and now injectable aesthetics—empowering strong regional practices like DermFx to thrive alongside larger groups through accessible, high-impact real-world evaluation and protocols.”
Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile1.
For more information about ALOHA, visit https://obagi-professional.com.
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,2 Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About DermFx
DermFx is a top-ranked medical spa in Orange County and Los Angeles, specializing in advanced aesthetic treatments including injectables, lasers, non-surgical body contouring, and skin rejuvenation. Founded by Erin Alonso, MSN, FNP, with over 25 years of experience in aesthetic medicine, DermFx operates five convenient locations in Southern California and has served tens of thousands of satisfied patients over 20+ years. Known for exceptional patient care, five-star service, and a commitment to confidence-building results, DermFx combines cutting-edge technology with personalized protocols to refresh, restore, and rejuvenate. For more information, visit https://www.dermfx.com.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
Source: Waldencast plc
1 Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
2 Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
FAQ**
How might the partnership between DermFx and Obagi Medical impact the growth trajectory of Waldencast Acquisition Corp. WALD in the Southern California aesthetic market?
What specific strategies does Waldencast Acquisition Corp. WALD plan to implement to maximize the real-world data generated through the ALOHA Program?
In what ways could the innovative injectable solutions from Obagi Medical influence consumer perception of Waldencast Acquisition Corp. WALD in the competitive skincare industry?
How does the collaboration with DermFx align with Waldencast Acquisition Corp. WALD’s broader vision of developing purpose-driven beauty and wellness brands?
**MWN-AI FAQ is based on asking OpenAI questions about Waldencast Acquisition Corp. (NASDAQ: WALD).
NASDAQ: WALD
WALD Trading
-1.91% G/L:
$1.54 Last:
19,807 Volume:
$1.54 Open:
